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Long noncoding RNA and its contribution to autism spectrum 
disorders








































Recent	 studies	have	 indicated	 that	 long	noncoding	RNAs	 (lncRNAs)	play	 important	
roles	in	multiple	processes,	such	as	epigenetic	regulation,	gene	expression	regulation,	





nome.	Recent	 studies	have	also	 suggested	 that	 lncRNAs	are	more	abundant	 in	 the	
human	brain	and	are	involved	in	neurodevelopment	and	neurodevelopmental	disor-












Diagnostic	 and	 Statistical	 Manual	 of	 Mental	 Disorders,	 5th	 Edition	
(DSM-	5)	 because	 of	 the	 heterogeneity	 of	 both	 clinical	 features	 and	






The	 etiologies	 of	 ASDs	 are	 complex	 and	 not	 well	 understand	
to	 date.	 Genetic	 and	 environmental	 factors,	 both	 alone	 and	 in	
646  |     TANG eT Al.
combination,	have	been	 implicated	 in	 the	pathogenesis	of	ASDs.6-10 
Mutations	 in	 many	 genes,	 including	 neuroligin-	3	 (NLGN3),	 neuroli-
gin-	4	(NLGN4),	neurexin-	1	(NRXN1),	SH3	and	multiple	ankyrin	repeat	
domains	 protein	 2	 (SHANK2),	 SH3	 and	multiple	 ankyrin	 repeat	 do-
mains	protein	3	(SHANK3),	Parkinson	protein	2	(PARK2),	MACRO	do-
main	containing	2	(MACROD2),	and	semaphorin-	5A	(SEMA5A),	have	














For	 example,	Wang	 et	al.11	 reported	 that	 hypermethylation	 of	 the	
enolase	2	 (ENO2)	gene	 is	present	 in	15%	of	patients	with	ASDs.	 It	




shown	 that	 lncRNAs	perform	a	wide	variety	of	 functions,	 including	




physiological	 and	 developmental	 processes,	 as	well	 as	 the	 etiology	
of	many	disorders	and	complex	diseases.23-25	Currently,	full	and	sys-
tematic	discussions	of	the	relationship	between	lncRNAs	and	ASDs	
are	 highly	 limited.	 Therefore,	 this	 review	 summarizes	 the	 available	
information	from	previous	outstanding	publications	with	a	focus	on	
the	contribution	of	lncRNAs	to	ASDs	and	to	other	genetic	syndromes,	
such	 as	 FXS	 and	RTT,	which	 have	 a	 similar	 clinical	 presentation	 to	
ASDs.
2  | LNCRNAS AND THEIR MECHANISMS 
OF ACTION
LncRNAs,	which	are	defined	as	untranslated	RNA	molecules	greater	
than	200	nucleotides	 in	 length,	 can	 be	 derived	 from	 sense	 or	 anti-
sense	 strands	 within	 protein-	coding	 genes,	 intergenic	 regions,	 or	
pseudogenes.	 LncRNAs	 are	 spliced	 and	 processed	 so	 that	 they	 in-
clude	a	5′-	methyl-	guanosine	cap	and	3′-	poly	(A)	tail	once	transcribed.	
LncRNAs	can	be	localized	to	the	nucleus	or	the	cytoplasm,	but	many	
lncRNAs	 are	 expressed	with	 temporal	 and	 tissue	 and/or	 cell	 speci-
ficity.24	 LncRNAs	 have	 a	 poorly	 conserved	 primary	 structure	 but	
relatively	 well-	conserved	 secondary	 structure	 and	 splicing.26,27 The 
mechanisms	of	action	of	lncRNAs	are	diverse	and	not	yet	fully	under-
stand,	 but	mainly	 include	 genetic	 imprinting,	 chromatin	 remodeling,	
cell	cycle	regulation,	splicing	regulation,	mRNA	degradation	and	trans-




that	 lncRNAs	 are	 key	 components	 of	 numerous	 cellular	 processes.	
Generally,	 lncRNAs	 regulate	 gene	 expression	 at	 three	 levels:	 tran-
scriptional	 regulation,	 posttranscriptional	 regulation	 and	 epigenetic	
regulation.30






stranded	 complex	with	 a	 regulatory	 sequence,32	 by	 regulating	 RNA	





2.2 | LncRNAs regulate RNA processing and 
translation
LncRNAs	play	a	role	not	only	in	transcriptional	regulation	but	also	
in	 posttranscriptional	 regulation.	 They	 can	 regulate	 pre-	mRNA	
splicing	 through	 the	 isolation	 of	 splicing	 factors	 or	 by	 regulating	
the	distribution	and	phosphorylation	of	splicing	factors	in	splicing	










peptide.40	 High	 levels	 of	 β-	amyloid	 peptide	 plaques	 in	 the	 brain	
are	a	 prominent	 feature	 of	Alzheimer’s	 disease.41	Thus,	 BACE-	AS	
participates	in	the	pathological	process	of	Alzheimer’s	disease.40
2.3 | LncRNAs participate in epigenetic regulation
Epigenetic	regulation	results	 in	a	change	in	gene	expression	without	
changing	 the	nucleotide	 sequence	of	 the	gene.	Common	epigenetic	
phenomena	include	DNA	methylation,	gene	silencing,	histone	modifi-
cation,	genomic	imprinting	and	RNA	editing.	LncRNAs	have	received	




RNA,	 including	 demethylation)	 activates	 TCF21	 expression	 by	 in-
ducing	demethylation	of	the	TCF21	promoter.	 In	addition	to	TCF21,	
TARID	 can	 also	 interact	 with	 GADD45A	 (growth	 arrest	 and	 DNA-	
damage-	inducible,	 alpha).	 GADD45A	 regulates	 DNA	 demethylation	
by	 recruiting	 thymine-	DNA-	glycosylase,	 which	 activates	 transcrip-
tional	 activity.43,44	The	 lncRNAXist	 (X	 chromosome	 inactive	 specific	
transcript)	 inhibits	 gene	 expression	 on	 the	 inactive	 X	 chromosome	
by	regulating	methylation	of	target	genes.45	 In	another	example,	the	
lncRNAs	AIR	 and	Kcnqlotl	 induce	 histone	modification	 through	 the	
recruitment	of	histone-	modifying	enzymes	that	can	affect	target	gene	
expression.46,47
3  | LNCRNAS IN THE CENTRAL NERVOUS 
SYSTEM (CNS) AND BRAIN
The	vertebrate	CNS	contains	an	enormous	diversity	of	neuronal	and	
glial	cell	types	that	differentiate	and	form	networks	through	an	in-
tricate	 developmental	 program	 that	must	 coordinate	 intrinsic	 and	
extrinsic	 stimuli	 to	 achieve	 proper	 form	 and	 function.48	 LncRNAs	
have	been	 shown	 to	 be	highly	 expressed	within	 the	 central	 nerv-
ous	system,	particularly	in	the	brain,	where	they	sometimes	exhibit	
specific	 spatiotemporal	 expression	 patterns.49	 Cells	 in	 the	 CNS	
show	 strong	 expression	 of	 lncRNAs,	 with	 5458	 of	 a	 total	 9747	
lncRNA	 transcripts	 detected	 in	 the	 human	 brain,	 including	 ~40%	
of	the	most	highly	and	differentially	expressed	lncRNAs.48,50 These 
lncRNAs	 have	 been	 shown	 to	 be	 involved	 in	 several	 key	 aspects	
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of	 brain	 development	 and	 function,	 such	 as	 synaptogenesis,	 neu-




LncRNAs	 are	 emerging	 as	 key	 regulators	 of	 neurogenesis.	 Loss-	
of-	function	studies	performed	in	embryonic	stem	cells	(ESCs)	and	in-
duced	pluripotent	 stem	cells	 (iPSCs)	 have	 found	 that	 differentiation	











Sox2	 to	 coregulate	 a	 large	pool	 of	 downstream	genes	 implicated	 in	
neurogenesis.60
Formation	of	functional	synapses	 is	the	fundamental	process	re-
quired	 for	 establishing	 neural	 circuits	 and	 ultimately	 for	 expressing	
complex	behavior.	This	process	is	characterized	by	increased	prolifera-
tion	of	neuronal	cells	and	overproduction	of	synaptic	connections.61,62 
Aberrant	 regulation	of	 synaptogenesis	 is	more	commonly	 seen	 than	
aberrant	 regulation	 of	 neurogenesis	 in	many	 neurological	 disorders,	
such	 as	 ASDs	 and	 schizophrenia.63	 The	 lncRNA	 MALAT1,	 which	
has	 been	 reported	 to	 be	 enriched	 in	 neurons	 and	 nuclear	 speckles,	
regulates	 synaptic	 density	 and	 the	 expression	 levels	 of	 neuroligin	 1	
(NLGN1)	and	synaptic	cell-	adhesion	molecule	 (SynCAM1)	by	regula-
tion	of	serine/arginine-	rich	splicing	factor.38
The	 critical	 balance	 between	 excitation	 and	 inhibition	 in	 the	
brain	 is	 maintained	 by	 two	 major	 classes	 of	 neurons:	 excitatory	
projection	 neurons	 and	 inhibitory	 local	 circuit	 interneurons.64 
GABA	primarily	mediates	 inhibition;	 thus,	GABAergic	 interneuron	
function	has	been	associated	with	many	neurodevelopmental	and	









is	 a	 key	 regulator	 of	members	 of	 the	DLX	 family	 of	 transcription	
factors	 that	 are	 involved	 in	 GABAergic	 neuronal	 differentiation.	
Mariani	and	colleagues	reported	that	DLX6-	AS1	were	upregulated	
in	cerebral	organoids	derived	from	iPSCs	made	from	patents	with	
ASDs.71	A	 recent	 study	 has	 also	 revealed	 that	 DLX6-	AS1	 upreg-
ulated	 in	cerebral	organoids	derived	 from	the	autism	gene	CHD8	
knockout	iPSCs.72






to	be	 involved	 in	other	genetic	 syndromes	 that	are	associated	with	
or	cause	a	predisposition	toward	ASDs,	such	as	fragile	X	syndrome,	
Rett	 syndrome,	Down	 syndrome,	Angelman	 syndrome,	 and	Prader-	
Willi	syndrome.
4.1 | LncRNAs and ASDs
ASD	 is	 a	 clinically	 and	 etiologically	 heterogeneous	 disorder	 with	
a	 complex	 genetic	 architecture.	 In	 the	 last	 decade,	 several	 studies	
have	observed	aberrant	expression	of	 lncRNAs	 in	both	postmortem	






lated.	 Functional	 pathway	 analysis	 of	 those	 lncRNAs	 revealed	 that	
synaptic	 vesicle	 cycling	 and	 transport	 were	 primarily	 involved,	 and	




transcribed	 from	 the	ASD	 susceptibility	 genes	 SHANKs	 and	BDNF,	
were	also	differentially	expressed.73
To	date,	 there	have	been	two	studies	 in	which	brain	tissue	from	
ASD	 subjects	was	 assessed	 for	 changes	 in	 regulatory	 lncRNAs.74,75 
Ziats	 and	 colleagues	 performed	microarray	 profiling	 of	 over	 33	000	
annotated	lncRNAs	and	30	000	mRNA	transcripts	from	postmortem	
prefrontal	cortex	and	cerebellum	tissue	from	autistic	and	control	sub-







text	of	 imaging	 studies	of	 autistic	 brains,	which	have	 indicated	 that	
there	are	fewer	specialized	regions	in	autistic	brains	than	in	the	brains	
of	healthy	subjects.76	The	sample	size	in	this	study	was	small,	giving	
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48	individual	with	ASD	and	49	controls,	which	was	known	as	having	
the	largest	samples.	The	data	suggested	that	60	lncRNAs	were	differ-































SHANK2-	AS Regulation	of	SHANK2 Homo	sapiens [72]











FMR5 Unknown,	sense	to	FMR1 Homo	sapiens [87]
FMR6 Unknown,	antisense	to	FMR1 Homo	sapiens [87]


























MKRN3-	AS1 Antisense	to	and	genomic	imprinting	of	ZNF127 Homo	sapiens [126]
(Continues)








which	 is	 from	the	5p14.1	chromosomal	 region.	This	 region	contains	
the	 single-	nucleotide	 polymorphism	 (SNP)	 rs4307059,	 which	 was	
identified	by	the	GWAS	as	having	a	strong	association	with	ASDs.77 
MSNP1AS	is	94%	identical	and	antisense	to	the	X	chromosome	tran-
script	MSN.	MSN	encodes	 a	 protein	 (moesin)	 that	 regulates	 neuro-
nal	 architecture	 and	 immune	 response.	 Individuals	 who	 carry	 the	
ASD-	associated	 rs4307059	 T	 allele	 have	 increased	 expression	 of	
MSNP1AS.	 MSNP1AS,	 which	 binds	 to	 MSN,	 was	 highly	 expressed	




DISC2	 and	 ST7OT1-	2,	 have	 also	 been	 linked	with	ASDs.79,80 These 
studies	provide	a	new	perspective	on	the	identity	and	function	of	ln-
cRNAs	that	are	associated	with	ASDs.
4.2 | LncRNAs and Fragile X syndrome
Fragile	X	syndrome,	a	common	cause	of	inherited	intellectual	disabil-
ity	 and	ASD,	 is	 inherited	 via	 an	 X-	linked	 dominant	mechanism	 and	
is	 characterized	 by	moderate	 to	 severe	mental	 retardation,	 macro-	
orchidism	(the	normal	testicular	volume	is	20	mL,	while	50%	of	fragile	
X	 patients	 had	 testicular	 volumes	 of	 30-	50	mL),	 and	 large	 ears	 and	



























HAR1A Antisense	to	RELN,	the	role	is	unknown	in	SZ Homo	sapiens [143]
HAR1B Antisense	to	RELN,	the	role	is	unknown	in	SZ Homo	sapiens [143]























































of	 the	FMR1	promoter,	while	FMR6	 is	an	antisense	 transcript	over-
lapping	 the	3′UTR	of	FMR1.	FMR5	 is	 expressed	 similarly	 in	 several	
human	 brain	 regions	 from	 unaffected	 individuals	 and	 from	 full	 and	
premutation	patients.	However,	FMR6	is	silenced	in	 individuals	with	
a	 full	mutation	 or	 a	 premutation,	 suggesting	 abnormal	 transcription	
and/or	chromatin	remodeling	prior	to	transition	to	the	full	mutation.	
Furthermore,	the	expression	of	FMR4,	FMR5,	and	FMR6	was	found	
to	be	detectable	 in	 the	majority	 of	 patient	 leukocyte	RNA	 samples,	
suggesting	that	it	may	be	feasible	to	use	these	lncRNAs	as	biomarkers	
for	fragile	X	syndrome.
4.3 | LncRNAs and Down syndrome




essential	 in	 female	mammals,	 and	 nature	 has	 evolved	 a	mechanism	
to	compensate	for	the	difference	in	number	of	X-	linked	gene	copies	
between	 females	 and	males.91	XIST(X-	inactive	 specific	 transcript)	 is	
a	 conserved	 lncRNA	 that	 is	 produced	 exclusively	 from	 the	 inactive	
X	chromosome	and	“paints”	the	interphase	chromosome	structure.92 
XIST	 induces	 numerous	 heterochromatin	 modifications	 and	 archi-
tectural	 changes	and	 then	 recruits	polycomb-	group	protein	 to	 tran-
scriptionally	silence	the	inactive	X	chromosome.93-95	A	notable	recent	
report	from	Jiang	and	coworkers	described	the	use	of	genome	editing	





of	 “chromosome	 therapy.”96	 A	 study	 conducted	 by	 Celine	 and	 col-
leagues	showed	that	the	lncRNA	XACT	is	expressed	from	and	“coats”	
the	 active	 X	 chromosome	 in	 human	 pluripotent	 cells.97	 XIST	 and	










4.4 | LncRNAs and Rett syndrome
Rett	syndrome	(RTT)	is	an	X-	linked	postnatal	neurological	disorder	of	
the	gray	matter	of	the	brain,	which	almost	exclusively	affects	females	










regulated	 in	MeCP2-	null	mice	 brains.	 Additionally,	 this	 overexpres-
sion	of	AK081227	was	associated	with	downregulation	of	the	Gabrr2	
(gamma-	aminobutyric	acid	receptor	subunit	Rho	2)	gene,	which	is	the	





4.5 | LncRNAs, Angelman syndrome, and Prader- 
Willi syndrome
Angelman	 syndrome	 (AS)	 is	 a	 neurodevelopmental	 disorder	 charac-








expression	of	UBE3A,	 is	 transcribed	antisense	 to	UBE3A,109,110 and 
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high	expression	of	UBE3A-	ATS	is	detected	in	AS	patients	and	mouse	
models.111,112	Additionally,	many	studies	have	demonstrated	that	re-






stature,	 developmental	 delays,	 intellectual	 disability	 and	 behavioral	










target	 of	 rapamycin	 (mTOR)	 and	 the	 circadian	 genes	 Clock,	 crypto-
chrome	circadian	clock1	(Cry1)	and	period	circadian	clock	2	(Per2).120 
Another	 lncRNA,	 IPW,	which	 is	 transcribed	 from	 the	 15.q11.2-	q13	
region	of	the	chromosome	is	a	regulator	of	the	delta-	like	1	homolog-	
deiodinase	3	(DLK1-	DIO3)	regions.	Overexpression	of	IPW	in	subjects	
with	PWS	and	 in	parthenogenetic	 iPSCs	 resulted	 in	downregulation	
of	MEGs	 in	 this	 locus.	Of	 note,	 the	 gene	 changes	 are	 due	 to	 chro-
matin	modifications,	 rather	 than	DNA	methylation.121-123	Moreover,	
a	 series	 of	 investigations	 have	 also	demonstrated	 that	 the	 lncRNAs	
H19,	C15orf2,	MKRN3-	AS1,	 and	UBE3A-	AS1	may	be	 implicated	 in	
the	development	of	PWS.124-127
4.6 | LncRNAs and other neurodevelopmental 
disorders that is associated with autistic traits
In	 the	 last	 decade,	 some	 rare	 neurodevelopmental	 disorders	 have	













nit	 alpha1	 C	 (CACNA1C),132	 B-	cell	 CLL/lymphoma	 11A	 (BCL11A),	






lenge	 facing	 the	 life	 sciences	 is	 to	determine	 the	 function	of	genes	
and	 their	 regulatory	 networks.	 The	 discovery	 of	 functional	 roles	 of	
lncRNAs	not	only	provides	a	new	pathway	for	researching	the	growth	
and	development	of	organisms	but	also	provides	a	prospect	 for	 the	
development	 of	 tissue	 engineering	 technology	 and	 novel	 targeted	
gene	therapy	technology.	LncRNAs	are	important	to	the	CNS	because	
they	play	 roles	 in	maintenance	of	pluripotency,	 cell	 fate,	neurogen-
esis	 and	 migration,	 synaptogenesis,	 neuron-	specific	 relaxation	 of	
epigenetic	 imprinting,	 repression	of	neural	genes	 in	nonneural	 cells,	
and	brain	tissue	patterning.135	Because	long-	term	memory	formation	
is	based	on	the	alteration	of	chromatin	structure,	 lncRNAs	are	even	
involved in memory.136,137	The	involvement	of	 lncRNAs	in	neurode-
velopmental	and	neurodegenerative	disorders	and	other	neurological	
diseases	further	 illustrates	their	 important	role	 in	CNS	development	





and	 temporal	 expression	 patterns	 of	 lncRNAs	 and	 fully	 illustrating	
the	dynamics	of	lncRNAs	in	the	development	of	the	CNS	system	and	
in	 neurological	 disorders;	 and	 (iii)	 studying	 how	 lncRNAs	modulate	
pathogenetic	 events	 in	 neurodevelopmental	 disorders.	 Additionally,	
lncRNA	research	should	not	be	limited	to	animal	or	cellular	models.139 
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